FUT8

Alpha-(1,6)-fucosyltransferase is an enzyme that in humans is encoded by the FUT8 gene.[5][6]

FUT8
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesFUT8, fucosyltransferase 8, CDGF, CDGF1
External IDsOMIM: 602589 MGI: 1858901 HomoloGene: 9650 GeneCards: FUT8
Orthologs
SpeciesHumanMouse
Entrez

2530

53618

Ensembl

ENSG00000033170

ENSMUSG00000021065

UniProt

Q9BYC5

Q9WTS2

RefSeq (mRNA)

NM_001252614
NM_001252615
NM_001252616
NM_016893

RefSeq (protein)

NP_001239543
NP_001239544
NP_001239545
NP_058589

Location (UCSC)Chr 14: 65.41 – 65.74 MbChr 12: 77.28 – 77.52 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

This enzyme belongs to the family of fucosyltransferases. The product of this gene catalyzes the transfer of fucose from GDP-fucose to N-linked type complex glycopeptides. This enzyme is distinct from other fucosyltransferases which catalyze alpha1-2, alpha1-3, and alpha1-4 fucose addition. The expression of this gene may contribute to the malignancy of cancer cells and to their invasive and metastatic capabilities. Alternatively spliced variants encoding different isoforms have been identified.[6]

Kyowa Hakko Kirin's "Potelligent" platform uses a CHO cell line in which FUT8 has been knocked out to make afucosylated monoclonal antibodies.[7]

References

  1. GRCh38: Ensembl release 89: ENSG00000033170 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000021065 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Costache M, Apoil PA, Cailleau A, Elmgren A, Larson G, Henry S, Blancher A, Iordachescu D, Oriol R, Mollicone R (Dec 1997). "Evolution of fucosyltransferase genes in vertebrates". J Biol Chem. 272 (47): 29721–8. doi:10.1074/jbc.272.47.29721. PMID 9368041.
  6. "Entrez Gene: FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase)".
  7. Yu, X; Marshall, MJE; Cragg, MS; Crispin, M (June 2017). "Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering" (PDF). BioDrugs. 31 (3): 151–166. doi:10.1007/s40259-017-0223-8. PMID 28466278. S2CID 3722081.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.